At the news
? BEARISHIMPACT 6/10 COURT-RULING filed Jul 23, 2026 at 20:00 ET
Novo Nordisk suffered a series of adverse rulings in the Griffin Health Services product liability case on July 24, 2026. The court denied Novo Nordisk's motions to preclude the plaintiff's expert witness (Dr. Goldhaber), denied its motion to strike that expert, denied its second motion for summary judgment (finding it duplicative and in violation of court orders), and granted summary judgment only on the narrow indemnification count while denying it on all other claims, including design defect, failure to warn, negligence, and negligent misrepresentation. The case now proceeds to trial on the core product liability claims, creating material litigation risk for Novo Nordisk's insulin pen franchise in the U.S. market.
- The court denied Novo Nordisk's motion to preclude the plaintiff's expert witness, Dr. Goldhaber, finding him qualified to testify on warnings.
- The court denied Novo Nordisk's motion to strike Dr. Goldhaber's report and for renewal of summary judgment, calling it an untimely motion to reconsider.
- The court granted summary judgment only on the indemnification count (Count Five), but denied it on all other claims: design defect, failure to warn, negligence, negligent misrepresentation, and breach of implied warranty.
- The court denied Novo Nordisk's second motion for summary judgment as duplicative and in violation of the court's scheduling order, and criticized Novo Nordisk's counsel for misleading and unsupported statements.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access